title: A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.
abstract: The early bactericidal activities (EBAs) of 300 mg isoniazid, 18.5 mg isoniazid, 600 mg rifampicin and 800 mg ofloxacin given daily to 262 patients with newly diagnosed pulmonary tuberculosis in Cape Town, Nairobi, Madras and Hong Kong were measured by counting cfu and total acid-fast bacilli in sputum collections taken pre-treatment (S1), at 2 days (S3) and at 5 days (S6). In Cape Town, Nairobi and Madras, the cfu findings suggested that isoniazid produced a massive kill, perhaps of actively growing organisms, during the first 2 days (mean S1-S3 EBAs of 0.636-1.006) but was almost inactive thereafter (mean S3-S6 EBAs of 0.000-0.081), whereas rifampicin maintained moderate activity against slowly growing organisms throughout the 5 days (mean S3-S6 EBAs of 0.242-0.305). This finding suggests that EBAs measured during the 2-5 day interval might be able to assess the sterilizing activity of drugs. Ofloxacin had moderately high mean S1-S3 EBAs of 0.130-0.391. However, in Hong Kong rifampicin appeared to be the most bactericidal drug from the start, possibly because patients had more chronic disease. A method of adjusting the cfu EBAs using total counts was devised which decreased the variability between patients within a treatment group without altering the mean cfu EBA. This resulted in a large gain in precision in Hong Kong, suggesting that their estimates were greatly affected by type II variation, due to dilution of pus by saliva and bronchial secretions, whereas small or no gains were obtained in the other three centres, suggesting that the main cause of variability was type I, due to other factors.
authors.affiliation: Medical Research Council, Tygerberg, South Africa.
authors.forename: F A
authors.initials: FA
authors.lastname: Sirgel
authors.forename: P R
authors.initials: PR
authors.lastname: Donald
authors.forename: J
authors.initials: J
authors.lastname: Odhiambo
authors.forename: W
authors.initials: W
authors.lastname: Githui
authors.forename: K C
authors.initials: KC
authors.lastname: Umapathy
authors.forename: C N
authors.initials: CN
authors.lastname: Paramasivan
authors.forename: C M
authors.initials: CM
authors.lastname: Tam
authors.forename: K M
authors.initials: KM
authors.lastname: Kam
authors.forename: C W
authors.initials: CW
authors.lastname: Lam
authors.forename: K M
authors.initials: KM
authors.lastname: Sole
authors.forename: D A
authors.initials: DA
authors.lastname: Mitchison
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000494:pharmacology; D000904:Antibiotics, Antitubercular / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D007194:India / Q000453:epidemiology; D007538:Isoniazid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D015242:Ofloxacin / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D013019:South Africa / Q000453:epidemiology; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology / Q000382:microbiology*
chemical_list: D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D015242:Ofloxacin; D007538:Isoniazid; D012293:Rifampin